Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jul;52(7):637-43.
doi: 10.1111/j.1469-8749.2010.03628.x. Epub 2010 Feb 19.

Genotype does not predict severity of behavioural phenotype in juvenile neuronal ceroid lipofuscinosis (Batten disease)

Heather R Adams  1 , Christopher A Beck, Erika Levy, Rachel Jordan, Jennifer M Kwon, Frederick J Marshall, Amy Vierhile, Erika F Augustine, Elisabeth A de Blieck, David A Pearce, Jonathan W Mink
Affiliations

Genotype does not predict severity of behavioural phenotype in juvenile neuronal ceroid lipofuscinosis (Batten disease)

Heather R Adams et al. Dev Med Child Neurol. 2010 Jul.

Erratum in

  • Dev Med Child Neurol. 2010 Oct;52(10):890

Abstract

Aim: The primary aim of this investigation was to examine genotype and clinical phenotype differences in individuals with juvenile neuronal ceroid lipofuscinosis (JNCL) who were homozygous for a common disease-causing deletion or compound heterozygous. The secondary aim was to cross-validate the Child Behavior Checklist (CBCL) and the Unified Batten Disease Rating Scale (UBDRS), a disease-specific JNCL rating scale.

Method: Sixty individuals (28 males, 32 females; mean age 15y 1mo, SD 4y 9mo, range 5y 8mo--31y 1mo) with JNCL completed the UBDRS.

Results: No significant genotype and clinical phenotype differences were identified when comparing individuals homozygous for the deletion with a heterogeneous group of compound heterozygous individuals. There were significant correlations among related behaviour items and scales on the CBCL and UBDRS (Spearman's rho ranging from 0.39 [p<0.05] to 0.72 [p<0.01]). Behaviour and physical function ratings were uncorrelated, supporting divergent validity of these two constructs in JNCL.

Interpretation: Previous reports of genotype and clinical phenotype differences were unsupported in this investigation, which did not find differences between individuals homozygous or heterozygous for the CLN3 deletion. The CBCL, an already validated measure of behaviour problems, appears valid for use in JNCL and cross-validates well with the UBDRS.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Box plots of the median United Batten Disease Rating Scale (UBDRS) behaviour problems score by genotype group.
See this image and copyright information in PMC

References

    1. Boustany R-M. Batten disease or neuronal ceroid lipofuscinosis. In: Moser HW, editor. Handbook of Clinical Neurology. Elsevier Science; Amsterdam: 1996. pp. 671–700.
    1. Santavuori P, Lauronen L, Kirveskari E, Åberg L, Sainio K, Autti T. Neuronal ceroid lipofuscinoses in childhood. Neurol Sci. 2000;21(Suppl 3):S35–41. - PubMed
    1. Phillips SN, Benedict JW, Weimer JM, Pearce DA. CLN3, the protein associated with batten disease: structure, function and localization. J Neurosci Res. 2005;79:573–83. - PubMed
    1. Adams H, de Blieck EA, Mink JW, Marshall FJ, Kwon J, Dure L, et al. Standardized assessment of behavior and adaptive living skills in juvenile neuronal ceroid lipofuscinosis. Dev Med Child Neurol. 2006;48:259–64. - PubMed
    1. Adams H, Kwon J, Marshall FJ, de Blieck EA, Pearce DA, Mink JW. Neuropsychological symptoms of Juvenile-onset Batten disease: experiences from two studies. J Child Neurol. 2007;22:621–627. - PMC - PubMed

Publication types